The allogeneic therapy, CYAD-211 from Celyad Oncology, is unique insofar that it uses short-hairpin RNA (shRNA) editing to knock down the CD37 component of the T-cell receptor (TCR). It is a first-in-class CAR-T candidate, meaning it would represent the first CAR-T therapy that uses this gene-editing approach.